Elite Pharmaceuticals Inc Stock Price, News & Analysis

Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products, with a focus on oral solid dose formulations. The ELTP news page on Stock Titan aggregates company press releases and related coverage so readers can follow Elite’s disclosures about its operations, products, and regulatory milestones.

Recent news from Elite highlights several key themes. The company regularly reports financial results for its fiscal year and subsequent quarters, noting the impact of lisdexamfetamine product sales and growth in Elite label product lines on revenues and operating income. Elite also announces conference calls to discuss these results, providing dial-in details and inviting stockholder questions in advance.

Product and regulatory developments are another major news category. Elite has reported FDA approval of an Abbreviated New Drug Application for a generic version of Requip XL (Ropinirole Extended-Release Tablets USP) and has announced the commercial launch of a generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII). The company has also disclosed positive bioequivalence study results for an undisclosed anticoagulant generic drug product and its intention to file an ANDA with the FDA.

Operational updates, such as the first shipment of product from Elite’s FDA-approved expanded campus in Northvale, New Jersey, and details about its new packaging line, also appear in the news flow. Investors and observers who want a consolidated view of ELTP-related announcements can use this page to review financial updates, FDA and ANDA developments, new product launches, and facility expansion news in one place.